Loading...
Loading...
HGEN| Name | Value |
|---|---|
| Revenues | 1.0M |
| Cost of Revenue | 0.0M |
| Gross Profit | 1.0M |
| Operating Expense | 21.6M |
| Operating I/L | -20.5M |
| Other Income/Expense | -0.7M |
| Interest Income | 0.0M |
| Pretax | -21.3M |
| Income Tax Expense | 0.0M |
| Net Income/Loss | -21.3M |
Humanigen, Inc. is a clinical-stage biopharmaceutical company specializing in developing lenzilumab, an antibody targeting granulocyte-macrophage colony-stimulating factor (GM-CSF), for the treatment of cytokine storm associated with COVID-19. The company has completed a Phase 3 study and is conducting a Phase 2/3 study sponsored by the NIH. Additionally, lenzilumab is being studied in conjunction with CD19-targeted CAR-T cell therapies and for other inflammatory conditions such as acute Graft versus Host Disease, eosinophilic asthma, and rheumatoid arthritis. Humanigen's pipeline also includes ifabotuzumab, targeting EphA3, and HGEN005, targeting EMR1, for various applications in oncology and eosinophilic diseases.
